Eli Lilly and Company has acquired Ajax Therapeutics for $2.3 billion. This corporate acquisition brings together Eli Lilly, a global pharmaceutical company known for its diverse portfolio, with Ajax Therapeutics, a biotechnology firm focused on developing novel next-generation therapies for hematologic cancers.
Ajax Therapeutics specializes in pursuing uniquely selective approaches to develop novel next-generation therapies for hematologic cancers, particularly myeloproliferative neoplasms (MPNs). The company leverages deep cancer and structural biology insights combined with advanced computational drug discovery and protein structure platforms. Its primary focus is on developing next-generation JAK2 inhibitors to address significant unmet needs for patients with myelofibrosis (MF), including those resistant or refractory to existing JAK2 therapies. Ajax's lead clinical candidate, AJ1-11095, is the first Type II JAK2 inhibitor to enter clinical trials, currently in a Phase I study in the US for patients who have been failed by a Type I JAK2 inhibitor.
This acquisition is strategically significant for Eli Lilly, expanding its oncology pipeline with innovative approaches to challenging blood cancers. Ajax's expertise in Type II JAK2 inhibitors and its lead candidate, AJ1-11095, represent a potential advancement in treating MPNs, a disease area with persistent unmet patient needs driven by aberrant JAK/STAT signaling. The integration is expected to create synergies by combining Ajax's specialized scientific platform and early-stage clinical asset with Eli Lilly's extensive resources, global development capabilities, and commercialization infrastructure, accelerating the potential delivery of these novel therapies to patients.
The combined entity aims to advance the development of AJ1-11095 and other potential therapies from Ajax's pipeline, with the goal of providing more effective and disease-modifying treatment options for patients suffering from myelofibrosis and other hematologic malignancies.